Rare molecular events and difficult targets in NSCLC

Speaker: Maurice Pérol

M. Pérol digs into rare molecular alterations in NSCLC, altogether they encompass over 5-7% of genetic aberrations in lung adenocarcinoma. He elaborates the current problems in testing for rare molecular events and possible solutions. Furthermore, he discuss the clinical efficacy of already existing targeted drugs for such targets and the problems of off-label prescription. The most frequent target in NSCLC is unfortunately undruggable at the moment; he emphasized in that regard importance of collaborative efforts.

Discussion Points

  • Molecular landscape of NSCLC beyond EGFR and ALK
  • Which molecular events are so far difficult to target ad why?
  • Which molecular events are rare, but the targeted drugs exist and are approved for other cancer types?
  • Future perspectives